Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) Patents (Class 424/141.1)
Human (Class 424/142.1)
Binds receptor (Class 424/143.1)
Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tpa, etc.), or fibrin (Class 424/145.1)
Binds enzyme (Class 424/146.1)
Binds virus or component thereof (Class 424/147.1)
Binds bacterium or component thereof or substance produced by said bacterium (Class 424/150.1)
Binds parasitic organism (i.e., parasitic protozoan, multicellular ectoparasite (e.g., flea, tick, mite, etc.), or multicellular endoparasite (e.g., parasitic worm, etc.)) or component thereof or substance produced by said parasitic organism (Class 424/151.1)
Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell (Class 424/152.1)
  • PlGF-1 assay and kits and components thereof
    Patent number: 8741287
    Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: June 3, 2014
    Assignee: Abbott Laboratories
    Inventors: Susan E. Brophy, Lianli Chi, Saul A Datwyler, David J. Hawksworth, Don M. Laird, Sharmila Manoj, Mary S. Pinkus, Dominick L. Pucci, Carol S. Ramsay, David C. Sogin, Bailin Tu, Zhiguang Yu, Robert N. Ziemann, Lowell J. Tyner
  • Methods of treating vasomotor symptoms using antibodies
    Patent number: 8734802
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 27, 2014
    Assignee: Labrys Biologics, Inc.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Subtypes of humanized antibody against interleukin-6 receptor
    Patent number: 8734800
    Abstract: An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH2 (447), and an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH2 (447), and a pharmaceutical composition comprising them.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: May 27, 2014
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Katsuhiro Kano, Isamu Terashima
  • Carrier immunoglobulins
    Patent number: 8734796
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: May 27, 2014
    Assignee: Amgen Inc.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas C. Boone, Frederick W. Jacobsen, HoSung Min, Jane Talvenheimo, Taruna Arora, Janet Doellgast
  • Anti-TLR4 antibodies and methods of use thereof
    Patent number: 8734790
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: May 27, 2014
    Assignee: Novimmune SA
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
  • Antibodies for epidermal growth factor receptor 3 (HER3)
    Patent number: 8735551
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Andrew Paul Garner, Elizabeth Anne Reisinger Sprague, Seth Alexander Ettenberg, Christian Kunz, Nicole Haubst, Winfried Elis
  • Function modifying NAv 1.7 antibodies
    Patent number: 8734798
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: May 27, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J Wolff
  • Optimized fc variants and methods for their generation
    Patent number: 8734791
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Reagents and treatment methods for autoimmune diseases
    Patent number: 8734792
    Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: May 27, 2014
    Assignee: Duke University
    Inventor: Thomas F. Tedder
  • AGENTS AND METHOD FOR TREATING INFLAMMATION-RELATED CONDITIONS AND DISEASES
    Publication number: 20140141005
    Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: LOMA LINDA UNIVERSITY
    Inventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
  • ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF
    Publication number: 20140140990
    Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.
    Type: Application
    Filed: March 28, 2012
    Publication date: May 22, 2014
    Applicants: National Research Council of Canada, Alethia Biotherapeutics Inc.
    Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
  • Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
    Patent number: 8728523
    Abstract: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 20, 2014
    Assignee: DePuy Synthes Products, LLC
    Inventors: Mohamed Attawia, Thomas M. DiMauro, Hassan Serhan, Sudhakar Kadiyala, David Urbahns, Scott Bruder
  • Methods for treating inflammatory bowel disease
    Patent number: 8728475
    Abstract: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-? are disclosed, as are other methods.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 20, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Timothy Zheng
  • Methods of preventing or treating pain using anti-NGF antibodies
    Patent number: 8728473
    Abstract: Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 20, 2014
    Assignee: Alderbio Holdings LLC
    Inventors: Leon F. Garcia-Martinez, John A. Latham, Ethan W. Ojala, Corinne C. Akatsuka, Pei Fan, Jeffrey T. L. Smith, Benjamin H. Dutzar
  • Treatments for cancer
    Patent number: 8728468
    Abstract: The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing melanoma tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF).
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 20, 2014
    Assignee: FibroGen, Inc.
    Inventors: Suzanne M. Spong, Thomas B. Neff, Stephen J. Klaus
  • Immunopotentiative composition
    Patent number: 8728474
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: May 20, 2014
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Human tissue factor antibody and uses thereof
    Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Cell and therapeutical and diagnostical methods based thereon
    Patent number: 8722045
    Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 13, 2014
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
  • Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof
    Patent number: 8722041
    Abstract: This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 13, 2014
    Assignee: Governors of the University of Alberta
    Inventors: Marit L. Sandvold, Finn Myhren, Carol E. Cass, James D. Young
  • Tweak receptor
    Patent number: 8722051
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 13, 2014
    Assignee: Immunex Corporation
    Inventor: Steven R. Wiley
  • Method for the potentiation of opioid analgesics effects on pain
    Patent number: 8715666
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: May 6, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • Epitopes
    Patent number: 8715663
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Amgen Inc.
    Inventors: Christopher J. Paszty, Hsieng Sen Lu
  • Fully human antibodies against human 4-1BB
    Patent number: 8716452
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same
    Patent number: 8715670
    Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 6, 2014
    Assignee: Hanwha Chemical Corporation
    Inventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
  • Treatment of angiogenesis disorders
    Patent number: 8715660
    Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: May 6, 2014
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Kim Png
  • Treatment of celiac disease with IgA
    Patent number: 8709413
    Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: April 29, 2014
    Inventor: Michael R. Simon
  • Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
    Patent number: 8709422
    Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2).
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: April 29, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
  • Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
    Patent number: 8709409
    Abstract: A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: April 29, 2014
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Osamu Okuda, Noriaki Yoshida, Revinder Nath Maini
  • Antibodies to non-functional P2Xreceptor
    Patent number: 8709425
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: April 29, 2014
    Assignee: Biosceptre International Limited
    Inventors: Julia Alexander Barden, Angus Gidley-Baird
  • PCSK9 antagonists
    Patent number: 8710192
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 29, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
  • Method for treating Crohn's disease by administering an anti-IL-12 antibody
    Patent number: 8703141
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: April 22, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
    Patent number: 8703139
    Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 22, 2014
    Assignee: Universitaet Basel
    Inventors: Karl Hofbauer, Jean Christophe Peter
  • Inhibition of factor B, the alternative complement pathway and methods related thereto
    Patent number: 8703140
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 22, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Gilkeson
  • Targeted cryptosporidium biocides
    Patent number: 8703134
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 22, 2014
    Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Treatment of tauopathies
    Patent number: 8703137
    Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 22, 2014
    Assignee: Intellect Neurosciences Inc.
    Inventor: Daniel G. Chain
  • Antibodies of the ED-B domain of fibronectin, their construction and uses
    Patent number: 8703143
    Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 22, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
  • Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)
    Patent number: 8703138
    Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: April 22, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Ping Wang
  • Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
    Patent number: 8697076
    Abstract: Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 15, 2014
    Assignees: Northwestern University, Intellect Neurosciences Inc.
    Inventors: Lester I. Binder, Daniel G. Chain, Yifan Fu, Kristina Patterson
  • Identification and engineering of antibodies with variant Fc regions and methods of using same
    Patent number: 8697071
    Abstract: The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc?R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 15, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Jeffrey Stavenhagen, Sergey Gorlatov, Christopher Rankin, Nadine Tuaillon
  • Cancer specific antibody and cell surface proteins
    Patent number: 8697075
    Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: April 15, 2014
    Assignee: Viventia Bio Inc.
    Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
  • Antibodies that inhibit metalloproteins
    Patent number: 8697078
    Abstract: The present application relates to antibodies which recognize [2(2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: April 15, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Netta Sela-Paswell, Tamar Danon, Raanan Margalit
  • IgE antibodies for the treatment of cancer
    Patent number: 8697079
    Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: April 15, 2014
    Assignees: Quest Pharma Tech Inc., The Regents of the University of California
    Inventors: Manuel L. Penichet, Birgit C. Schultes, Christopher F. Nicodemus, Tracy R. Daniels, Gustavo Helguera, Jose A. Rodriguez
  • Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
    Patent number: 8697073
    Abstract: Disclosed are: an anti-podoplanin antibody which has a high binding activity and a high effector activity and has low antigenicity in humans or mice; and others. Specifically disclosed are: a chimeric antibody comprising an anti-podoplanin antibody for which an epitope is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 (excluding rat NZ-1 antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:3), and a heavy chain complementarity determining region and a light chain complementary determining region of the anti-podoplanin antibody; and others.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 15, 2014
    Assignee: Fujifilm RI Pharma Co., Ltd.
    Inventors: Yukinari Kato, Mika Kato, Yasuhiko Nishioka
  • 1D05 PCSK9 antagonists
    Patent number: 8697070
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 15, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Method for treating synovial sarcoma
    Patent number: 8697068
    Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: April 15, 2014
    Assignee: Oncotherapy Science, Inc
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Chikako Fukukawa, Motoki Kuhara
  • Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
    Publication number: 20140099319
    Abstract: Methods and compositions of the invention relate to the treatment of diabetic nephropathy and associated disorders. In particular, the methods and compositions use a pharmaceutical-grade galactose-pronged carbohydrate or pharmaceutical compositions thereof alone or in combination with other therapeutic agents.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 10, 2014
    Applicant: Galectin Therapeutics, Inc.
    Inventor: Peter G. Traber
  • NLRR-1 antagonists and uses thereof
    Patent number: 8691222
    Abstract: NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Meredith Hazen, Jo-Anne S. Hongo, Victoria Smith, Susanna Stinson
  • Antibody molecules having binding specificity for human IL-13
    Patent number: 8691233
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: April 8, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
    Patent number: 8691231
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Ulrik Nielsen, Shannon Werner, Jeffrey David Kearns
  • SILK-BASED DRUG DELIVERY SYSTEM
    Publication number: 20140093580
    Abstract: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicants: EIDGENOSSISCHES TECHNISCHE HOCHSCHULE (THE SWISS FEDERAL INSTITUTE OF TECHNOLOGY), TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Lorenz Meinel